CABA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Cabaletta Bio Inc (CABA) is not a strong buy for a beginner investor with a long-term perspective at this time. While there are positive developments in clinical trials and analyst ratings remain optimistic, the company's financial performance is weak, and technical indicators suggest the stock is overbought. Additionally, there are no strong proprietary trading signals or significant institutional or insider trading trends to support an immediate buy decision.
The stock is showing bullish momentum with MACD above 0 and expanding positively, and moving averages indicating an uptrend (SMA_5 > SMA_20 > SMA_200). However, the RSI of 84.99 indicates that the stock is overbought, suggesting a potential pullback in the short term. Key resistance levels are at 3.479 and 3.701, while support levels are at 2.761 and 2.539.
Successful infusion of rese-cel into the first two patients, marking significant progress in clinical trials.
FDA approval for an IND amendment for clinical manufacturing.
Analyst ratings remain positive, with Guggenheim raising the price target to $16 and Morgan Stanley maintaining an Overweight rating.
Financial performance remains weak, with negative net income and declining EPS.
RSI indicates overbought conditions, suggesting a potential short-term pullback.
No significant hedge fund or insider trading trends to indicate strong institutional support.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$41.92M (improved by 28.64% YoY), and a decline in EPS to -0.4 (-36.51% YoY). Gross margin remains at 0%.
Guggenheim raised the price target to $16, citing robust efficacy data and clinical execution. Morgan Stanley lowered the price target to $13 but maintains an Overweight rating, highlighting ongoing progress and expected positive updates throughout 2026.
